Key Events This Week
22 Jun: Stock opens at ₹1,696.00 after valuation shift announcement
23 Jun: Valuation upgrade to fair; stock rebounds +4.10%
24 Jun: Hits upper circuit limit with 5.0% gain amid strong buying
25 Jun: Surges to new 52-week high at ₹1,946.1, upper circuit hit again
22 June 2026: Week Opens on a Correction Amid Valuation Recalibration
Venus Remedies Ltd began the week at ₹1,696.00, down 3.60% from the previous close of ₹1,759.40. This decline followed the announcement of a valuation shift to a fair grade, reflecting a recalibration of key metrics such as price-to-earnings (P/E) and price-to-book value (P/BV). Despite the dip, the stock remained well above its 52-week low of ₹417.65, signalling sustained investor confidence in its long-term prospects. The Sensex, in contrast, gained 0.46% to close at 36,342.26, highlighting the stock’s initial underperformance relative to the broader market.
23 June 2026: Valuation Upgrade Spurs Strong Rebound
On 23 June, Venus Remedies Ltd rebounded sharply, gaining 4.10% to close at ₹1,765.55. This recovery was driven by the market’s positive reaction to the company’s upgraded valuation grade from expensive to fair, supported by a P/E ratio of 22.05 and a P/BV of 3.42. The stock’s improved price attractiveness relative to peers in the Pharmaceuticals & Biotechnology sector helped fuel buying interest. Notably, the Sensex declined 1.05% to 35,959.97, underscoring Venus Remedies’ outperformance amid broader market weakness. Trading volume increased to 5,260 shares, reflecting renewed investor participation.
Strong fundamentals, solid momentum, fair price – This Large Cap from the NBFC sector checks every box for our Top 1%. This should definitely be on your radar!
- - Complete fundamentals package
- - Technical momentum confirmed
- - Reasonable valuation entry
24 June 2026: Upper Circuit Hit Amid Robust Buying Pressure
Venus Remedies Ltd surged to hit its upper circuit limit on 24 June, closing at ₹1,853.45, a 4.98% gain from the previous day. The stock traded within a range of ₹1,770.1 to ₹1,856.5, reflecting strong upward momentum. Despite the price surge, delivery volumes declined by 57.33% compared to the five-day average, suggesting a significant portion of the buying was speculative or intraday. The stock outperformed the Pharmaceuticals & Biotechnology sector, which rose only 0.26%, and the Sensex, which gained 0.53%. Technical indicators showed the stock trading comfortably above all key moving averages, signalling sustained bullish sentiment. The regulatory freeze triggered by the upper circuit hit indicated excess demand and heightened investor conviction.
25 June 2026: New 52-Week High and Second Upper Circuit Surge
On 25 June, Venus Remedies Ltd reached a new 52-week and all-time high of ₹1,947.10, hitting the upper circuit limit again with a 5.0% gain. The stock’s intraday high of ₹1,946.1 marked a significant milestone, reflecting a cumulative return of 14.75% over the last three trading sessions. Trading volume rose to 55,931 shares, generating a turnover of approximately ₹10.60 crore. Despite some intraday profit-booking pressure, the stock closed firmly at the upper price band. The company’s net-debt free status, strong operating profit growth of 45.72% annually, and a 126.19% increase in net profit for the quarter ending March 2026 underpin the rally. Institutional investors increased their stake by 0.72% to 4%, signalling growing confidence. Technical indicators including MACD, Bollinger Bands, and Dow Theory signals remain bullish, although the monthly RSI suggests some caution in the medium term.
Want to dive deeper on Venus Remedies Ltd? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-06-22 | Rs.1,696.00 | -3.60% | 36,342.26 | +0.46% |
| 2026-06-23 | Rs.1,765.55 | +4.10% | 35,959.97 | -1.05% |
| 2026-06-24 | Rs.1,853.45 | +4.98% | 36,151.68 | +0.53% |
| 2026-06-25 | Rs.1,945.90 | +4.99% | 36,133.32 | -0.05% |
Key Takeaways
Valuation Shift Enhances Price Attractiveness: The upgrade from an expensive to a fair valuation grade, supported by a P/E of 22.05 and P/BV of 3.42, has improved the stock’s appeal relative to sector peers.
Strong Technical Momentum: Consecutive upper circuit hits and trading above all major moving averages confirm robust bullish sentiment and sustained buying interest.
Exceptional Financial Performance: Net profit growth of 126.19% in the latest quarter and operating profit growth of 45.72% annually underpin the stock’s rally and justify premium valuations.
Micro-Cap Volatility and Liquidity: Despite strong gains, delivery volumes have declined, indicating speculative trading and the need for cautious monitoring of liquidity and price swings.
Conclusion
Venus Remedies Ltd’s 10.60% weekly gain amid a broadly flat Sensex highlights the stock’s strong outperformance driven by improved valuation metrics, solid financial results, and technical strength. The achievement of new 52-week highs and repeated upper circuit hits reflect heightened investor confidence and positive market sentiment. While the micro-cap status introduces volatility and liquidity considerations, the company’s net-debt free position, consistent profitability, and growing institutional participation provide a solid foundation for the current momentum. Investors should continue to monitor volume trends and technical signals to gauge the sustainability of this rally within the Pharmaceuticals & Biotechnology sector.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
